115 related articles for article (PubMed ID: 21190159)
1. Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
Testino G; Borro P
Hepatology; 2011 Apr; 53(4):1409-10. PubMed ID: 21190159
[No Abstract] [Full Text] [Related]
2. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis.
Testino G; Sumberaz A; Ancarani AO; Borro P; Ravetti G; Ansaldi F; Andorno E; Gentile R; Icardi G
Hepatogastroenterology; 2009; 56(90):501-3. PubMed ID: 19579629
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
[No Abstract] [Full Text] [Related]
4. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.
Testino G; Sumberaz A; Ravetti G; Gentile R; Ansaldi F; Icardi G
Dig Liver Dis; 2006 Nov; 38(11):864-5. PubMed ID: 16945599
[No Abstract] [Full Text] [Related]
6. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
7. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
[TBL] [Abstract][Full Text] [Related]
8. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
[No Abstract] [Full Text] [Related]
9. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Jian Wu Y; Shu Chen L; Gui Qiang W
Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
[TBL] [Abstract][Full Text] [Related]
10. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
[TBL] [Abstract][Full Text] [Related]
11. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon and ribavirin for hepatitis C.
Abramowicz M
N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
[No Abstract] [Full Text] [Related]
13. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
Gholam PM
N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
[No Abstract] [Full Text] [Related]
14. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
[No Abstract] [Full Text] [Related]
15. [The study of optimal treatment in patients with refractory chronic hepatitis C].
Chen XY; Zhang YH
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):488-9. PubMed ID: 19912679
[No Abstract] [Full Text] [Related]
16. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
Kim SR; Saito J; Imoto S; Komaki T; Nagata Y; Nakajima T; Ando K; Fukuda K; Otono Y; Kim KI; Ohtani A; Sugimoto K; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Maekawa Y; Hayashi Y; Kudo M
Digestion; 2011; 84 Suppl 1():5-9. PubMed ID: 22156479
[TBL] [Abstract][Full Text] [Related]
17. A success story with chronic hepatitis C.
Weekley D; Yuen JC
J Ark Med Soc; 2005 Dec; 102(6):158-9. PubMed ID: 16381402
[No Abstract] [Full Text] [Related]
18. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
Wedemeyer H; Cornberg M; Manns MP
Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
[No Abstract] [Full Text] [Related]
19. Chronic hepatitis C virus infection.
Flamm SL
JAMA; 2003 May; 289(18):2413-7. PubMed ID: 12746366
[No Abstract] [Full Text] [Related]
20. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Lenzi M; Bianchi FB
Aliment Pharmacol Ther; 2005 Nov; 22(10):943-9. PubMed ID: 16268968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]